HCW Biologics (NASDAQ: HCWB)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-12 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.060 | ||||||
REV | 3.118M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of HCW Biologics (NASDAQ: HCWB) through any online brokerage.
Other companies in HCW Biologics’s space includes: Alzamend Neuro (NASDAQ:ALZN), Orchard Therapeutics (NASDAQ:ORTX), Galectin Therapeutics (NASDAQ:GALT), Bolt Biotherapeutics (NASDAQ:BOLT) and Gemini Therapeutics (NASDAQ:GMTX).
The latest price target for HCW Biologics (NASDAQ: HCWB) was reported by Maxim Group on Thursday, March 24, 2022. The analyst firm set a price target for 4.00 expecting HCWB to rise to within 12 months (a possible 87.79% upside). 2 analyst firms have reported ratings in the last year.
The stock price for HCW Biologics (NASDAQ: HCWB) is $2.13 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for HCW Biologics.
HCW Biologics’s Q2 earnings are confirmed for Friday, August 12, 2022.
There is no upcoming split for HCW Biologics.
HCW Biologics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.